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Trained immunity as a novel therapeutic strategy
Vera P Mourits1, Jac CHM Wijkmans2, Leo AB Joosten1 and
Mihai G Netea1,3
Recent studies have shown that upon certain vaccinations or
infections human innate immune cells can undergo extensive
metabolic and epigenetic reprogramming, which results in
enhanced immune responses upon heterologous re-infection,
a process termed trained immunity. Trained immunity has also
been shown to be inappropriately activated in inflammatory
diseases. This provides the potential for identifying novel
therapeutic targets: potentiation of trained immunity could
protect from secondary infections and reverse immunotolerant
states, while inhibition of trained immunity might reduce
excessive immune activation in chronic inflammatory
conditions. By targeting specific mechanisms of trained
immunity on either immunologic, metabolic or epigenetic level,
novel therapeutic approaches could be developed.
Addresses
1Department of Internal Medicine and Radboud Center for Infectious
Diseases, Radboud University Medical Center, Nijmegen, The
Netherlands
2 INNTREST Consultancy BV, Oss, The Netherlands
3Department for Genomics & Immunoregulation, Life and Medical
Sciences Institute (LIMES), University of Bonn, Bonn, Germany
Corresponding author: Netea, Mihai G (mihai.netea@radboudumc.nl)
Current Opinion in Pharmacology 2018, 41 [1_TD$DIFF]:52– [2_TD$DIFF]58
This review comes from a themed issue on Immunomodulation
Edited by Ed Lavalle and James McLachlan
For a complete overview see the Issue and the Editorial
Available online 24th April 2018
https://doi.org/10.1016/j.coph.2018.04.007
1471-4892/ã 2018 The Authors. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (https://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The ability to induce memory is an important feature of
the adaptive immune system, yet an increasing body of
evidence shows that the innate immune system is also
able to mount a memory response. It is known that plants
and insects, which lack adaptive immunity, show
enhanced nonspecific protection to reinfection [1–3].
Moreover, in Candida albicans vaccinated mice it has been
shown that a partial protection to reinfection can be
induced through T-cell and B-cell independent mecha-
nisms [4]. Recently, it has been shown that infections and
vaccinations are able to induce an enhanced immune
response in monocytes upon nonspecific restimulation,
a process termed trained immunity. b-Glucan, a major
cell wall component of C. albicans, as well as the Bacillus
Calmette-Gue´rin (BCG) vaccine are able to induce
trained immunity, whereas lipopolysaccharide (LPS)
stimulation in monocytes results in tolerance [5–7].
b-Glucan and BCG induce trained immunity in mono-
cytes via pattern recognition receptors (PRRs) dectin-1
and NOD2 respectively, leading to enhanced signaling of
the Akt (protein kinase B)–mTOR (mammalian target of
rapamycin)–HIF-1a (hypoxia-inducible factor-1a) path-
way, modifications in metabolic pathways, and epigenetic
rewiring [5,6] (Figure 1). Unfortunately, not only micro-
bial ligands can induce trained immunity after infection
or vaccination, but also endogenous ligands can inappro-
priately activate trained immunity, thereby contributing
to chronic inflammation, as has been shown in atheroscle-
rosis [8] or gout [9].
The recent insights in trained immunity could have
important implications for the development of novel
therapeutic targets for immune-mediated diseases. Inter-
estingly, BCG vaccinated children in West Africa show a
lower overall mortality by decreased morbidity due to
infections [10 [1_TD$DIFF] , and healthy volunteers vaccinated with
BCG show an enhanced pro-inflammatory cytokine pro-
file upon nonspecific restimulation in ex vivo monocytes,
persisting for at least three months [5]. Currently, indu-
cers of trained immunity are already used to treat dis-
eases, such as muramyl tripeptide (MTP) for osteosar-
coma [11] and BCG in bladder cancer [12] through
mechanisms that likely involve induction of autophagy
[13]. In addition to improvement of vaccines, it would be
very interesting to modulate trained immunity in humans
with maladaptive immune responses to restore a balanced
immune function.
In this review, wewill provide a short overview on the role
of trained immunity in the pathophysiology of diseases,
and discuss potential therapeutic targeting strategies in
the context of trained immunity on the immunological,
metabolic and epigenetic level.
Trained immunity in the pathophysiology of
diseases
Enhanced immune responses induced by trained immu-
nity, as reflected by an increased interleukin (IL)-6, IL-
1b, and tumor necrosis factor a (TNFa) production,
might lead in the long term to development and/or
persistence of chronic inflammatory conditions such as
arthritis or atherosclerosis. It is already known that a high
glucose environment drives a pro-inflammatory profile
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which remains even after introduction to a normal glucose
environment, called hyperglycemic memory [14]. Fur-
thermore, metformin, an mTOR inhibitor leading to
inhibition of trained immunity [15,16], is associated
with anti-inflammatory effects in atherosclerosis and is
administered to type 2 diabetes patients [17,18].
Recently, it has been shown that endogenous danger
ligands such as oxidized low density lipoprotein (oxLDL)
or lipoprotein A, both involved in the pathogenesis of
atherosclerosis, are able to induce training in monocytes
in vitro. By training monocytes with oxLDL, genes
involved in metabolic processes important for atherogen-
esis are induced, and histone methylation plays a crucial
role in the long-term persistence of these effects. The
trained monocytes have a propensity to differentiate into
foam cells and show enhanced expression of scavenger
receptors [8]. Moreover, a western type diet induces
trained immunity in a mice model for atherosclerosis,
which was dependent on the NLRP3 inflammasome.
This occurs already at the level of granulocyte-monocyte
precursors and persisted for several months [19].
By contrast, enhanced immune responses induced by
trained immunity might be beneficial in immunotolerant
states occurring in sepsis or cancer. In sepsis, an imbal-
anced interaction between epigenetic and metabolic
pathways in immune cells is observed [20], and in vitro
it has been shown that tolerized and trained macrophages
have a different epigenetic and metabolic state [15,21].
Importantly, the training stimulus b-glucan is able to
reverse LPS-induced tolerance in monocytes ex vivo
from volunteers with experimental endotoxemia, by
recovering the induction of 60% of tolerized genes
and reversing histone modifications [22]. Similarly,
tumor-associated macrophages have a long-term pheno-
type of anti-inflammatory M2 macrophages, and exert
inhibitory effects on CD8+ cytotoxic lymphocytes [23].
Therefore, inducers of trained immunity are of great
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interest as treatment to reverse immunotolerant states in
diseases such as sepsis or cancer (Figure 2).
Therapeutic strategies to target trained
immunity
Induction of trained immunity is achieved by interaction
of immunologic signaling, metabolic changes and epige-
netic modifications. Targeting these components for ther-
apeutic purposes represents an interesting novel approach
(Figure 3).
Immunological targets
Stimuli which are able to induce training could act as a
protective mechanism for subsequent infections by the
means of vaccinations, or as a therapeutic approach in
maladaptive immune states. b-Glucan as an inducer of
trained immunity for therapeutic purposes has already
entered clinical trials. Earlier studies suggest anticarcino-
genic effects [24] and increased resistance to infections
after b-glucan administration [25]. Although oral b-glucan
administration to healthy volunteers did not induce
trained immunity in monocytes ex vivo [26], intravenous
administration of clinical grade b-glucan has passed reg-
ulatory hurdles and is now in clinical trials for treatment of
cancer in combination with checkpoint inhibitors (Clini-
cal Trials database; Imprime PGG, U.S. National Library
of Medicine). In addition, BCG strongly induces trained
immunity in vaccinated healthy volunteers, as shown by
enhanced pro-inflammatory cytokine production in ex
vivo monocytes upon nonspecific reinfection [27]. As
mentioned before, BCG is currently administered to
patients with bladder cancer after transurethral resection
of the tumor [12]. Although the underlying mechanism is
unclear, activation of innate immune cells and production
of pro-inflammatory cytokines suggest a protective role of
trained immunity. This hypothesis is supported by the
fact that the synthetic mycobacterial structure MTP-
phosphatidylethanolamine (mifamurtide) has beneficial
effects and is approved for the treatment of osteosarcoma
to stimulate anticarcinogenic activity by macrophages
[11]. Additionally, the muramyl dipeptide (MDP) deri-
vate murabutide promotes non-specific protection to
bacterial and viral infections and decreases lethality of
mice injected with LPS [28], and paclitaxel conjugated to
MDP shows immunoenhancing capacity [29]. Liposome-
encapsulated MDP (or derivates) is able to migrate to an
inflammatory environment, and is therefore a promising
therapeutic strategy to target trained immunity responses.
In addition, another approach aims to inhibit intracellular
immunological pathways essential for training in mono-
cytes and macrophages, such as Akt–mTOR–HIF-1a
[15,16]. Everolimus, an mTOR activator rapamycin
analog, is currently used to treat various types of cancer
[30], and metformin is currently administered to type
2 diabetes patients [17]. Their beneficial effects likely
also involves modulation of trained immunity. Various
Akt and HIF-1a inhibitors are currently being studied,
however, no inhibitor is yet approved for administration
in humans, partially due to their complex regulatory
network [31]. Inhibition of kinases such as Raf-1 and
Rip2, or PI3K and ERK are of interest since they
are activated after triggering of dectin-1 and NOD2
receptors respectively, or by oxLDL. Importantly, it is
known that crosstalk and compensation between differ-
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is recommended when inhibiting signaling molecules.
Furthermore, inhibiting these proteins will have signifi-
cant consequences for other cellular processes due to their
complex interacting network.
Epigenetic targets
The development of epigenetic modulators is of great
interest due to accumulating evidence of the importance
of epigenetic regulation in various diseases, including
inflammatory conditions [32]. Targeting epigenetic modi-
fiers is interesting since epigenetic changes can be stably
maintained but are also able to adapt to changing envir-
onments. Moreover, epigenetic reprogramming is at the
basis of the long-term induced memory of innate immune
cells.
In b-glucan-induced trained monocytes, modifications in
histone 3 lysine 27 (H3K27) acetylation as well as H3K4
mono-methylation and trimethylation were observed in
gene promoters involved in trained immunity, resulting
in transcriptionally active chromatin [15,21,22]. Since
inhibiting histone methyltransferases abrogates b-glucan-
induced and BCG-induced training [5,6] this could be an
interesting therapeutic target. Although lysine-specific
demethylase 1 inhibition by pargyline did not influence
b-glucan-induced trained immunity [6], this could be due
to the poor inhibitory activity of pargyline at micromolar
concentrations [33]. On the other hand, the broad jumonji
histone demethylase inhibitor JIB-04 decreased
trained immunity responses through modulation of the
inhibitory histone modification H3K9 (Moorlag SJCFM,
et al. submitted), supporting the value of this therapeutic
strategy. Furthermore, the small molecule inhibitor of the
BET family of bromodomains I-BET151 (GSK
1210151A) is able to block LPS-induced tolerance when
co-administered in human monocytes in vitro, however it
could not reverse tolerance in a therapeutic manner if
tolerance was already induced by LPS and is therefore
probably not an effective treatment in monocytes that
already experienced an inflammatory response [22].
During b-glucan-induced trained immunity, lower
expression of sirtuins is also observed, which deacetylate
histones as well as non-histone targets [15]. Interest-
ingly, an increased NAD+/NADH ratio and lactate levels
are observed during training in monocytes, which are
able to respectively activate or inhibit histone deacety-
lases (HDACs) [34,35]. Induction of sirtuin-1 results in a
more anti-inflammatory state with increased fatty acid
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oxidation [35]. This suggests that sirtuin-1 might be
an interesting target in trained or tolerized monocytes.
Currently, the class I/II HDAC inhibitor vorinostat (sub-
eroylanilide hydroxamic acid) is approved for cancer
treatment [36], and multiple HDAC inhibitors, including
ITF-2357 and SAHA, have been shown to reduce inflam-
mation in inflammatory diseases [37]. Of note, certain
epigenetic enzyme inhibitors exhibit broad substrate
specificity, and enzymes might alter their function in
different cell types and environments, which may lead
to unwanted effects.
BCG is also able to induce trained immunity in NK cells
[38], which is accompanied with specific DNA methyla-
tion patterns as well as modulated cytokine responses in
CMV-infected individuals [39,40]. Although metabolites
such as fumarate, a-ketoglutarate (a-KG) and succinate,
which are able to affect the Ten-eleven translocation
(TET) family of DNA demethylases [41,42], accumulate
during training, no role for DNA methylation was
observed in b-glucan trained monocytes [22].
Micro (mi)RNAs have recently emerged as critical reg-
ulators of gene expression in immune cells. miRNAs
have a relatively long half-life and could therefore be
interesting in the context of trained immunity by their
persistence after removal of the primary stimulus, espe-
cially since myeloid cells have limited proliferative capac-
ity. miR-155 expression is increased in response to inflam-
matory signals and promotes M1 polarization and
inflammation [43], and miR-155 knock-out mice exhibit
early resistance to mycobacteria due to reduced growth of
bacteria in infected monocytes/macrophages [44]. miR-
146a, expression of which is increased following LPS
stimulation, is suggested to play a key role in endotoxin
tolerance by abrogating hyperinflammation [43]. Further-
more, various studies have described a role for long non-
coding (lnc)RNAs in innate immunity. For example,
lncRNA ANRIL correlates with severity in atherosclero-
sis [45], and long non-intergenic ncRNA Cox2 and
THRIL are respectively essential for TLR-induced
expression of IL-6 and regulation of TNFa in monocytes
[46,47]. Further understanding of the role of non-coding
RNAs is required to assess their function in the context of
trained immunity.
Metabolic targets
Modulation of energy metabolism is essential for func-
tioning of cells, and it is becoming increasingly clear that
during innate immune responses specific metabolic sig-
natures occur [48]. Both b-glucan and BCG-induced
training results in upregulation of aerobic glycolysis via
epigenetic modifications at essential glycolytic genes,
leading to an increased lactate production and increased
NAD+/NADH ratio [15,16,41]. Induction of gluta-
minolysis, aspartate and cholesterol synthesis pathways
are involved in b-glucan-induced trained immunity,
whereas oxidative phosphorylation (OXPHOS) plays a
minor role [15,41,49]. The metabolic switch from
OXPHOS towards aerobic glycolysis, called the Warburg
effect, is essential since inhibiting glycolysis inhibits
b-glucan-induced trained immunity in vitro [15].
Although OXPHOS is downregulated in b-glucan-
induced trained immunity, succinate, fumarate and
malate accumulate in monocytes [41]. Interestingly,
during BCG-induced training the metabolic changes
are dependent on epigenetic modifications at metabolic
genes, yet epigenetic changes are also dependent on the
induction of glycolysis and glutaminolysis [16], thereby
linking metabolic and epigenetic processes. Several
metabolites and metabolic enzymes can act as substrates
or cofactors for epigenetic-modifying enzymes (Table 1)
[42,50,51]. Of note, fumarate itself is able to induce
training in monocytes in vitro by increasing H3K4me3
andH3K27ac and inhibiting degradation of HIF-1a [41].
Moreover, the decreased expression of the lysine
demethylase (KDM) 5 family of HDACs, which are
responsible for H3K4 demethylation, is inhibited by
fumarate thereby maintaining accessible chromatin.
Interestingly, during tolerance no KDM5 activity is
observed, and this could be restored by a-KG, a cofactor
for KDMs [41]. Recently, it has been shown that b-glu-
can-induced trained immunity depends on mevalonate,
a metabolite of the cholesterol synthesis pathway.
Statins are able to block mevalonate and can thereby
prevent trained immunity. This could be very relevant for
Hyper-IgD syndrome (HIDS) patients which accumulate
mevalonate and have monocytes with a trained pheno-
type [52].
Altered metabolism in immune cells is observed in many
diseases, including cancer, for which currently multiple
agents targeting metabolism are in trials or approved for
cancer treatment [53]. Some of these drugs have also been
studied in the context of inflammation, such as drugs
which block the glycolysis pathway, 2-deoxy-D-glucose
and dichloroacetic acid [54], which are both able to
abrogate trained immunity in vitro [16]. Additionally,
administration of etomoxir, which blocks lipid metabo-
lism, as well as 6-diazo-5-oxo-L-norleucine (DON),
which inhibits glutamine uptake and metabolism, have
been shown to be beneficial in respectively graft versus
host disease and after transplantation to prevent rejection
56 Immunomodulation
Table 1
Metabolites/enzymes affect epigenetic enzymes.
Metabolite/enzyme Function
NAD+ Stimulate sirtuins (HDACs)
Acetyl-CoA Stimulate HATs
a-KG Stimulate TET family (DNMTs)
Inhibits KDMs
Succinate and fumarate Inhibits TET family (DNMTs)
Stimulate KDMs
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[54]. Toxicity is a main challenge in the development of
metabolic inhibitors. If this can be overcome, it would
be a very promising target in the context of trained
immunity.
Conclusions and future prospective
Therapeutic targeting of trained immunity on the immu-
nologic, metabolic or epigenetic level is a promising
strategy to treat maladaptive immune responses in
humans. Especially the development of epigenetic mod-
ulators is of great interest since epigenetic modifications
are dynamic and reversible, and are at the basis of long-
term trained immunity. In the future, knowledge needs to
be gained to better understand the mechanisms mediat-
ing trained immunity in specific diseases to develop novel
effective targeting strategies.
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